We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Global Market for Automated Tissue Diagnostics Expected to Surge

By LabMedica International staff writers
Posted on 04 Feb 2014
Print article
Image: The market for automated tissue diagnostics equipment (such as the Roche Benchmark XT analyzer pictured above) is expected to increase by over 30% in the next few years (Photo courtesy of Roche)
Image: The market for automated tissue diagnostics equipment (such as the Roche Benchmark XT analyzer pictured above) is expected to increase by over 30% in the next few years (Photo courtesy of Roche)
The market for automated tissue diagnostic products is expected to grow by more than 30% by the year 2017.

The growth in diagnostic test volume combined with an ongoing shortage of pathologists to perform sophisticated analytical tests favors the automation of anatomic pathology laboratories.

While increasing consolidation among laboratories and hospitals will escalate workloads and make a case for automated tissue diagnostic protocols, it will reduce the number of tissue diagnostics customers, forcing equipment manufacturers to compete aggressively for fewer accounts. Furthermore, reimbursement cuts impede the sale of high-end automated equipment in anatomic pathology laboratories. Nonetheless, the tissue diagnostics market, which earned approximately 2.39 billion USD in 2012, was estimated by Frost & Sullivan (Mountain View, CA, USA) to increase by more than 30% and reach 3.45 USD billion by 2017.

"The availability of tissue-based companion diagnostic tests is another important driver, especially for the US and European market," said Divyaa Ravishankar, life sciences industry analyst at Frost & Sullivan. "With companion diagnostic partnerships gathering pace, industry convergence has led to the addition of tissue diagnostics in the in vitro diagnostic portfolio of most of the pharmaceutical companies. Providing attractive procurement strategies can boost the uptake of high-end tools in this constrained environment. For instance, offering competitive monthly payments, tax benefits or incentives, and deferring payments to help overcome budgetary constraints will widen the consumer base of vendors in the global tissue diagnostics market."

Related Links:

Frost & Sullivan


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.